Obesity Today—June 9, 2026

This week’s Obesity update highlights regulatory and clinical progress, competitive efficacy data, oral therapy momentum, and expanding cardiometabolic strategies.

In this Newsletter

Dive deeper

🧬 Survodutide Phase 3 obesity and MASLD data [1] [07 Jun 2026]

https://www.boehringer-ingelheim.com/us/human-health/metabolic-diseases/positive-data-two-phase-iii-synchronize-obesity-trials
Context: SYNCHRONIZE-1 studied adults with obesity or overweight without type 2 diabetes, while SYNCHRONIZE-MASLD studied adults with overweight or obesity and MASLD.
Key point: Survodutide (Boehringer Ingelheim; glucagon/GLP-1 dual agonist) showed weight loss and liver-fat reductions across both Phase 3 trials.
Implication: May influence prescriber choice and payer reviews pending full data.

💉 Pfizer monthly berobenatide tolerability readout [2] [US • 06 Jun 2026]

https://www.reuters.com/legal/litigation/pfizers-monthly-obesity-shot-has-side-effect-profile-similar-wegovy-midstage-2026-06-06/
Context: Pfizer presented VESPER-3 mid-stage data for berobenatide, a monthly injectable obesity candidate acquired through Metsera.
Key point: Pfizer said berobenatide had a side-effect profile similar to Wegovy, with GI events mostly early and near dosing.
Implication: May influence prescriber choice and payer reviews pending full data.

🇨🇳 Ecnoglutide beats semaglutide in head-to-head study [3] [China • 08 Jun 2026]

https://www.prnewswire.com/apac/news-releases/head-to-head-study-validates-the-clinical-advantage-of-new-generation-biased-glp-1-ecnoglutide-delivers-35-greater-weight-loss-than-semaglutide-302793396.html
Context: SLIMMER-UP-SWITCH enrolled 163 adults with obesity across 17 China research centers.
Key point: Ecnoglutide (Sciwind Biosciences; cAMP-biased GLP-1 receptor agonist) showed greater Week 20 weight loss than semaglutide.
Implication: May influence prescriber choice and payer reviews pending full data.

❤️ Amgen Repatha diabetes subgroup at ADA [4] [US • 08 Jun 2026]

https://firstwordpharma.com/story/7536659
Context: VESALIUS-CV subgroup data covered 6,002 people with high-risk diabetes and elevated LDL-C without prior heart attack or stroke.
Key point: Repatha (Amgen; evolocumab) reduced first major cardiovascular events versus placebo when added to lipid-lowering therapy.
Implication: Could inform practice and payer discussions; interpretation depends on study design and confounding control.

💊 Ribupatide oral and injectable obesity data [5] [China • 07 Jun 2026]

https://www.biospace.com/press-releases/hengrui-pharma-and-kailera-therapeutics-present-ribupatide-clinical-data-at-ada-2026
Context: Hengrui reported China Phase 2 data for once-daily oral ribupatide, while Kailera presented Phase 1 bridging data for injectable ribupatide.
Key point: Ribupatide (Hengrui Pharma, Kailera; GLP-1/GIP dual agonist) supported China Phase 3 plans and global development.
Implication: May influence prescriber choice and payer reviews pending full data.

🧪 Ascletis ASC30, ASC37, and ASC39 obesity portfolio [6] [US • 07 Jun 2026]

https://www.prnewswire.com/news-releases/ascletis-reinforces-its-differentiated-obesity-portfolio-at-american-diabetes-association-ada-2026-scientific-sessions-showcasing-asc30-clinical-data-and-exciting-preclinical-findings-from-asc37-and-asc39-302793255.html
Context: Ascletis presented Phase 2 ASC30 data plus preclinical ASC37 and ASC39 findings at ADA 2026.
Key point: ASC30 showed dose-dependent weight loss in Phase 2, while ASC37 and ASC39 added oral peptide and amylin-receptor programs.
Implication: Signals pipeline investment and modality expansion.

🧫 Verdiva VRB-103 and VRB-104 preclinical obesity data [7] [US • 07 Jun 2026]

https://firstwordpharma.com/story/7534180
Context: Verdiva Bio presented preclinical data for VRB-103, a once-weekly oral amylin analog, and VRB-104, an amylin/GLP-1 dual agonist.
Key point: VRB-103 showed amylin-receptor selectivity in vitro, and VRB-104 showed preclinical body-weight effects in a diet-induced obesity model.
Implication: Signals pipeline investment and modality expansion.

📈 Wegovy pill passes 3 million US prescriptions [8] [US • 07 Jun 2026]

https://www.prnewswire.com/news-releases/wegovy-pill-prescriptions-surpass-3-million-1-filled-roughly-every-5-seconds-bringing-glp-1-therapy-to-people-with-obesity-previously-untreated-while-novo-nordisk-unveils-new-data-at-ada-2026-302793337.html
Context: Novo Nordisk said Wegovy pill became available in the US in January 2026 and passed 3 million prescriptions in just over five months.
Key point: More than 80% of new Wegovy pill prescriptions were reportedly for people new to GLP-1 therapy.
Implication: Could streamline initiation and adherence via remote prescribing and logistics.

🇰🇷 Daewon rises on quadruple-agonist obesity hopes [9] [Korea • 08 Jun 2026]

https://en.sedaily.com/finance/2026/06/08/daewon-pharmaceutical-defies-market-rout-jumps-19-percent
Context: Daewon Pharmaceutical rose despite a broader Korea market rout after highlighting ADA 2026 preclinical obesity research.
Key point: Daewon’s candidate combines gastrin with GLP-1, GIP, and glucagon receptor activity (clinical stage not specified).
Implication: Signals pipeline investment and modality expansion.

📘 Aleniglipron ACCESS Phase 2b publication [10] [US • 07 Jun 2026]

https://www.biospace.com/press-releases/structure-therapeutics-announces-publication-in-nature-medicine-highlighting-phase-2b-access-program-of-aleniglipron-for-obesity
Context: Structure Therapeutics published Phase 2b ACCESS data for aleniglipron in Nature Medicine alongside ADA 2026 presentation.
Key point: Aleniglipron (oral small-molecule GLP-1 receptor agonist) showed continued weight loss in an open-label extension interim analysis.
Implication: May influence prescriber choice and payer reviews pending full data.

🔭 Novo Nordisk CEO frames semaglutide beyond weight loss [11] [US • 07 Jun 2026]

https://fortune.com/2026/06/07/novo-nordisk-ceo-ozempic-wegovy-glp-weight-loss-longevity-aesthetics/
Context: Novo Nordisk CEO Maziar Mike Doustdar discussed semaglutide, longevity, and aesthetics at the ADA conference in New Orleans.
Key point: Doustdar said Novo is exploring whether semaglutide benefits beyond weight loss could place the company in a “longevity game.”
Implication: Signals pipeline investment and modality expansion.

Why it matters

Oral obesity programs are gaining visibility, with Wegovy pill, aleniglipron, ASC30, ribupatide oral, and Verdiva’s oral amylin work all featured.
Differentiation is shifting beyond weight loss toward liver fat, visceral fat, muscle preservation, tolerability, and cardiometabolic outcomes.
China-origin assets are prominent, including ecnoglutide, ribupatide, and Ascletis programs.
ADA 2026 reinforced obesity as a modality race, spanning GLP-1, glucagon/GLP-1, GLP-1/GIP, amylin, triple agonists, and quadruple agonists.

🚀 Accelerate your success. Contact us now

📂 Explore our case studies. See examples of our work.

💡 Read our insights. Learn from our latest reports and analysis

🧰 See our full range of services. Discover how we can help you.

📚 View the full Obesity archive on our research hub page

🎯 Catch up on the Top Obesity news from the past two weeks, curated by the LucidQuest team.

🎬 Watch on YouTube.

FAQ

What did Boehringer Ingelheim report for survodutide?

Boehringer reported positive Phase 3 data from SYNCHRONIZE-1 and SYNCHRONIZE-MASLD, including weight-loss and liver-fat findings. Survodutide remains investigational. [1]

How is Pfizer positioning berobenatide?

Pfizer is positioning berobenatide as a potential monthly GLP-1 obesity injection. The company said VESPER-3 showed a side-effect profile similar to Wegovy, with dose-escalation changes planned for late-stage testing. [2]

What is notable about ecnoglutide?

Sciwind said ecnoglutide, a cAMP-biased GLP-1 receptor agonist, produced greater Week 20 weight loss than semaglutide in a China head-to-head study. [3]

What is the update on Wegovy pill?

Novo Nordisk said Wegovy pill passed 3 million US prescriptions in just over five months, and most new prescriptions were for people new to GLP-1 therapy. [8]

What is aleniglipron’s next step?

Structure Therapeutics said ACCESS Phase 2b data support the design of a Phase 3 program expected to start in the third quarter of 2026. [10]

Entities / Keywords

Survodutide, BI 456906, Boehringer Ingelheim, glucagon/GLP-1 dual agonist, SYNCHRONIZE-1, SYNCHRONIZE-MASLD, MASLD, MASH
Berobenatide, Pfizer, Metsera, monthly GLP-1, VESPER-3, Wegovy comparator context
Ecnoglutide, Sciwind Biosciences, cAMP-biased GLP-1, SLIMMER-UP-SWITCH, semaglutide
Repatha, evolocumab, Amgen, VESALIUS-CV, high-risk diabetes, LDL-C, MACE
Ribupatide, HRS9531, KAI-9531, Hengrui Pharma, Kailera Therapeutics, GLP-1/GIP dual agonist
ASC30, ASC37, ASC39, Ascletis Pharma, oral GLP-1, oral triple agonist peptide, amylin receptor agonist
VRB-103, VRB-104, Verdiva Bio, oral amylin analog, amylin/GLP-1 dual agonist
Wegovy pill, semaglutide tablets, Novo Nordisk, GLP-1-naïve patients, Medicare GLP-1 Bridge
Daewon Pharmaceutical, quadruple agonist, gastrin, GLP-1, GIP, glucagon
Aleniglipron, Structure Therapeutics, ACCESS, oral small-molecule GLP-1 receptor agonist
Semaglutide, Ozempic, Wegovy, longevity, aesthetics, Maziar Mike Doustdar